Premium
Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature
Author(s) -
Liu Yisi,
Birch Stephen,
Newbold K. Bruce,
Essue Beverley M.
Publication year - 2018
Publication title -
the international journal of health planning and management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.672
H-Index - 41
eISSN - 1099-1751
pISSN - 0749-6753
DOI - 10.1002/hpm.2495
Subject(s) - medicine , rifapentine , psychological intervention , latent tuberculosis , incentive , regimen , adverse effect , incidence (geometry) , tuberculosis , intensive care medicine , family medicine , psychiatry , mycobacterium tuberculosis , physics , optics , pathology , economics , microeconomics
Summary Objectives We investigated the rates of initiation and completion of treatment for latent TB infection (LTBI), factors explaining nonadherence and interventions to improve treatment adherence in countries with low TB incidence. Design A systematic search was performed in PubMed and Embase. All included articles were assessed for risk of bias. A narrative synthesis of the results was conducted. Results There were 54 studies included in this review. The proportion of people initiating treatment varied from 24% to 98% and the proportion of people completing treatment varied from 19% to 90%. The main barriers to adherence included the fear or experience of adverse effects, long duration of treatment, financial barriers, lack of transport to clinics (for patients), and insufficient resources for LTBI control. While interventions like peer counseling, incentives, and culturally specific case management have been used to improve adherence, the proportion of people who initiate and complete LTBI treatment still remains low. Conclusion To further improve treatment and LTBI control and to fulfill the World Health Organization goal of eliminating TB in low‐incidence countries, greater priority should be given to the use of treatment regimens involving shorter durations and fewer adverse effects, like the 3‐month regimen of weekly rifapentine plus isoniazid, supported by innovative patient education and incentive strategies.